Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Envelope glycoprotein GP120 is a surface-exposed glycoprotein of the Human Immunodeficiency Virus (HIV), essential for viral entry into host cells. It mediates HIV's initial interaction with host cells through sequential binding to CD4 receptors and chemokine coreceptors (primarily CCR5 or CXCR4), leading to membrane fusion. Gp120 is a major target for neutralizing antibodies, but its extensive sequence variability, glycan shielding, and conformational flexibility pose significant challenges for vaccine development.
Target for neutralizing antibodies; inhibits viral entry.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Envelope Glycoprotein GP120 (gp120).